Geron Corp. (GERN:US), ordered this month to stop testing its experimental drug in blood disorders, received permission from U.S. regulators to continue a trial of the compound for a bone marrow disorder.
No new patients will be enrolled in the study of imetelstat for myelofibrosis because of the partial clinical hold by the U.S. Food and Drug Administration, the Menlo Park, California-based company said in a statement today. Current participants must show a clinical benefit to stay in the trial, Geron said.
Geron, which has no products on the market, plunged 62 percent on March 12 after the FDA halted trials of imetelstat in essential thrombocythemia, polycythemia vera and multiple myeloma. The regulator stopped the tests because of the possibility of liver damage, Geron said.
To contact the reporter on this story: Caroline Chen in New York at firstname.lastname@example.org
To contact the editors responsible for this story: Reg Gale at email@example.com Bruce Rule, Robert Valpuesta